{"entity":{"id":"patidegib","kind":"drug","name":"Patidegib","aka":["Saridegib (topical)","IPI-926"],"tldr":"Patidegib is a hedgehog-pathway blocker made into a skin gel. It is being tested in people with Gorlin syndrome, who grow dozens of basal cell carcinomas, to prevent new tumours without the hair loss, muscle cramps and taste loss that the oral drugs cause.","summary":"Patidegib is the topical formulation of saridegib (IPI-926), a Smoothened inhibitor first developed by Infinity Pharmaceuticals as an oral drug. PellePharm reformulated it as a 2 percent gel applied twice daily to the face. Because Gorlin (basal cell nevus) syndrome is caused by germline PTCH1 loss, every basal cell carcinoma depends on hedgehog signalling, and oral vismodegib prevents them but is poorly tolerated for long-term use.\n\nA phase 2 study in Gorlin syndrome reported fewer new surgically eligible basal cell carcinomas with the gel than with vehicle, and a phase 3 trial followed. It is named on the locally advanced basal cell carcinoma page as the prevention approach for patients with the syndrome.","status":"phase-3","asOf":"2026-09-17","links":[],"tags":["subtype-drugs-wave"],"related":["vismodegib","sonidegib"],"cancers":["locally-advanced-bcc"],"sections":[],"technologies":[],"targets":["smoothened"],"drugs":[],"companies":["pellepharm"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"modality":"Topical hedgehog pathway (SMO) inhibitor gel","mechanism":"A cyclopamine derivative that binds Smoothened and blocks hedgehog signalling in the skin; applied as a gel it reaches the basal cells where basal cell carcinomas start without the systemic side effects of oral hedgehog inhibitors.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/patidegib/","neighbours":{"drug":[{"id":"sonidegib","kind":"drug","name":"Sonidegib","route":"/drugs/sonidegib/"},{"id":"vismodegib","kind":"drug","name":"Vismodegib","route":"/drugs/vismodegib/"}],"cancer":[{"id":"locally-advanced-bcc","kind":"cancer","name":"Locally advanced and metastatic basal cell carcinoma","route":"/cancers/locally-advanced-bcc/"}],"target":[{"id":"smoothened","kind":"target","name":"Smoothened (hedgehog pathway)","route":"/targets/smoothened/"}],"company":[{"id":"pellepharm","kind":"company","name":"PellePharm","route":"/companies/pellepharm/"}]}}